TAK - יחס חוב להיוון בספרים Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical (TAK) represents a defensive asset with zero dependence on macroeconomics. The history of the debt-to-book capitalization ratio confirms financial stability, where 0.64 records a new level. This veteran Japanese behemoth relies on its leadership in plasma therapy and stringent patents. A diversified portfolio in oncology and R&D guarantees long-term stability for the country's largest holding.

Stable cash flow from rare disease medications provides Takeda Pharmaceutical (TAK) with high financial resilience, offsetting the risks of excessive leverage. The current value of 0.64 reflects the proportion of liabilities to market capitalization, allowing for a real-time assessment of the debt-to-enterprise value ratio to evaluate credit load and bankruptcy risk without waiting for quarterly reports.